| |  Online-Ressource |
|---|
| Verfasst von: | Krawczyk, Adalbert [VerfasserIn]  |
|---|
| | Arndt, Michaela [VerfasserIn] |
|---|
| | Große-Hovest, Ludger [VerfasserIn] |
|---|
| | Weichert, Wilko [VerfasserIn] |
|---|
| | Giebel, Bernd [VerfasserIn] |
|---|
| | Dittmer, Ulf [VerfasserIn] |
|---|
| | Hengel, Hartmut [VerfasserIn] |
|---|
| | Jäger, Dirk [VerfasserIn] |
|---|
| | Schneweis, Karl E. [VerfasserIn] |
|---|
| | Eis-Hübinger, Anna Maria [VerfasserIn] |
|---|
| | Roggendorf, Michael C. [VerfasserIn] |
|---|
| | Krauß, Jürgen [VerfasserIn] |
|---|
| Titel: | Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody |
|---|
| Verf.angabe: | Adalbert Krawczyk, Michaela A.E. Arndt, Ludger Grosse-Hovest, Wilko Weichert, Bernd Giebel, Ulf Dittmer, Hartmut Hengel, Dirk Jäger, Karl E. Schneweis, Anna M. Eis-Hübinger, Michael Roggendorf, and Jürgen Krauss |
|---|
| E-Jahr: | 2013 |
|---|
| Jahr: | April 8, 2013 |
|---|
| Umfang: | 6 S. |
|---|
| Fussnoten: | Gesehen am 27.10.2021 |
|---|
| Titel Quelle: | Enthalten in: National Academy of Sciences (Washington, DC)Proceedings of the National Academy of Sciences of the United States of America |
|---|
| Ort Quelle: | Washington, DC : National Acad. of Sciences, 1915 |
|---|
| Jahr Quelle: | 2013 |
|---|
| Band/Heft Quelle: | 110(2013), 17, Seite 6760-6765 |
|---|
| ISSN Quelle: | 1091-6490 |
|---|
| Abstract: | Despite the availability of antiviral chemotherapy, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections remain a severe global health problem. Of particular concern is the growing incidence of drug resistance in immunocompromised patients, which stresses the urgency to develop new effective treatment alternatives. We have developed a humanized monoclonal antibody (mAb hu2c) that completely abrogates viral cell-to-cell spread, a key mechanism by which HSV-1/2 escapes humoral immune surveillance. Moreover, mAb hu2c neutralized HSV fully independent of complement and/or immune effector cell recruitment in a highly efficient manner. Prophylactic and therapeutic administration of mAb hu2c completely prevented infection-related mortality of severely immunodeficient mice being challenged with a lethal dose of HSV-1. The high neutralization capacity of mAb hu2c was fully maintained toward clinical HSV isolates being multiresistant to standard antiviral drugs, and infection was fully resolved in 7/8 nonobese diabetic/SCID mice being infected with a multidrug resistant HSV-1 patient isolate. Immunohistochemical studies revealed no significant cross-reactivity of the antibody toward human tissues. These features warrant further clinical development of mAb hu2c as an immunotherapeutic compound for the management of severe and particularly drug-resistant HSV infections. |
|---|
| DOI: | doi:10.1073/pnas.1220019110 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1073/pnas.1220019110 |
|---|
| | Volltext: https://www.pnas.org/content/110/17/6760 |
|---|
| | DOI: https://doi.org/10.1073/pnas.1220019110 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | acyclovir resistance |
|---|
| | immunocompromised mice |
|---|
| | stem cell transplantation |
|---|
| K10plus-PPN: | 1752728513 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody / Krawczyk, Adalbert [VerfasserIn]; April 8, 2013 (Online-Ressource)
